AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan
Date:2022-01-29Source: AmoyDx


Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Pharmaceutical Company Limited in Japan as one of the companion diagnostics for Brigatinib, its tyrosine kinase inhibitor for identifying ALK+ patients with non-small cell lung cancer (NSCLC). Brigatinib is commercialized as Alunbrig in over 30 countries worldwide.

“Seven global pharmaceuticals have adopted PLC Panel as the companion diagnostics for their proprietary drug products. The shift from single to multi gene testing in PLC has reduced NSCLC testing turnaround time significantly and expedited patients access to targeted treatment. Brigatinib and ALK+ companion diagnostic represents another meaningful milestone to democratize NSCLC patients access for precision medicine” said Li-Mou Zheng, Ph.D., both Founder and Chief Executive Officer of AmoyDx. 

About the PLC Panel: The PLC Panel is based on polymerase chain reaction (PCR) technology and can simultaneously evaluate the presence of 11 driver genes (EGFR/ ALK/ ROS1/ KRAS/ BRAF/ HER2/ RET/ MET/ NTRK1/ NTRK2/ NTRK3 genes). In Japan, the PLC Panel has received approval for five driver genes (EGFR, ALK, ROS1, BRAF, and MET exon 14 skipping) for ten associated targeted therapies in Non-Small Cell Lung Cancer (NSCLC). Due to its high sensitivity, short turnaround time (TAT) and ease of use, the PLC Panel is expected to contribute to the planning of early treatment strategies and the expansion of treatment opportunities for NSCLC patients.

About Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685): Amoy Diagnostics Co., Ltd. is a pioneer and global leading company in the field of molecular diagnostics for precision oncology, focusing on companion diagnostics product development and commercialization. AmoyDx has a portfolio with more than twenty products approved by China’s NMPA, the EU regulatory authorities, Japan’s MHLW, South Korea’s MFDS, etc. Patients in more than 60 countries are benefiting from AmoyDx products. With multiple technological platforms and full capability for companion diagnostics product development and commercialization, AmoyDx has become an important diagnostics partner for many pharmaceutical companies around the globe. For more information, please visit

For more information, please call us at +86-592-6806835 or email us at

* Required information
Manage your account info
Change your password